Jundishapur J Microbiol
Jundishapur J Microbiol

article information

Jundishapur Journal of Microbiology: Vol.15, issue 11; e132821
published online: January 13, 2023
article type: Case Report
received: November 1, 2022
revised: December 26, 2022
accepted: December 27, 2022
DOI: https://doi.org/10.5812/jjm-132821
Crossmark

A Case-report of Concurrent Pulmonary and Cerebral Lesions in a Patient with Polymyositis: Invasive Aspergillosis or Astrocytoma?

authors:

avatar Shabnam Tehrani ORCID 1 , avatar Davood Yadegarynia ORCID 1 , avatar Amirreza Keyvanfar ORCID 1 , *

Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

how to cite: Tehrani S, Yadegarynia D, Keyvanfar A. A Case-report of Concurrent Pulmonary and Cerebral Lesions in a Patient with Polymyositis: Invasive Aspergillosis or Astrocytoma?. Jundishapur J Microbiol. 2022;15(11):e132821. https://doi.org/10.5812/jjm-132821.

Abstract

Introduction:

Polymyositis is an idiopathic inflammatory myopathy that mainly manifests itself with muscle weakness. Patients with polymyositis have a higher risk of developing infections and malignancies. We report concurrent pulmonary and cerebral lesions in a polymyositis patient with many diagnostic challenges.

Case Presentation:

A 56-year-old woman complained of a productive cough and dyspnea from two weeks ago. Her symptoms gradually progressed until a sudden loss of consciousness occurred. She was a known case of polymyositis and was treated with oral prednisolone. Imaging revealed concurrent pulmonary and cerebral lesions. Initially, the patient underwent empirical therapy. However, the patient underwent a bronchoscopy because she did not respond to treatment. Specimens obtained from respiratory secretions revealed branched septate hyphae, and the culture was positive for Aspergillus fumigatus. She was diagnosed with invasive aspergillosis, so we replaced the therapy with voriconazole. After three months, the lung lesions improved, but the number and extent of cerebral lesions increased. Finally, after a stereotactic biopsy, the patient was diagnosed with astrocytoma and became a candidate for radiotherapy.

Conclusions:

Patients with polymyositis are prone to contracting opportunistic infections and malignancies. Both of them can mimic each other and present diagnostic challenges to physicians. Thus, they should think about them for early diagnosis and timely treatment.

1. Introduction

Polymyositis is an idiopathic inflammatory myopathy that mainly occurs in adults. Polymyositis usually manifests itself with subacute proximal symmetrical muscle weakness. It may involve respiratory muscles contributing to respiratory insufficiency and aspiration pneumonia (1). Patients with polymyositis are also treated with immunosuppressive drugs (usually corticosteroids). As a result, they become susceptible to a broad spectrum of infections (2). Also, the literature has provided evidence that polymyositis is associated with several cancers (3). In this paper, we report concurrent pulmonary and cerebral lesions in a patient with polymyositis, whose diagnostic challenges are instructive for clinicians.

2. Case Presentation

A 56-year-old woman was referred to Labbafinejad Hospital (Tehran, Iran), complaining of productive cough and dyspnea from two weeks ago. Her symptoms gradually progressed until a sudden loss of consciousness occurred. She was a known case of polymyositis and was treated with oral prednisolone (12.5 mg daily) 18 months ago. The patient neither smoked nor consumed alcohol. On admission, the patient’s vital signs were as follows: Axillary temperature: 38.0°C, blood pressure: 110/70 mmHg, respiratory rate: 26 breaths/minute, the pulse rate: 90 beats/minute, and peripheral oxygen saturation: 87% on room air. The patient had a Glasgow coma scale of 13/15. Physical examination revealed only the use of accessory respiratory muscles.

Laboratory investigation manifested Leukocyte count = 17700 cells/mm3 with 87% neutrophil, hemoglobin = 11.3 mg/dL, platelet count = 123000 cells/mm3, erythrocyte sedimentation rate (ESR) = 90 mm/h, C-reactive protein (CRP) = 103 mg/L, serum creatinine = 0.9 mg/dL, serum galactomannan = 0.1 optical density index, and negative blood culture. The lung computed tomography (CT) scan depicted a central cavitary mass lesion in the left upper lobe (with somehow thick walls and soft margins without calcification) and pleural thickening and adjacent reticular pattern airspace opacification in the right lung (Figure 1). Furthermore, brain magnetic resonance imaging (MRI) showed an area of increased signal intensity with surrounding edema in the right frontal lobe with a mild mass effect (Figure 2A).

Initial lung computed tomography scan, a central cavitary mass lesion in the left upper lobe; pleural thickening and adjacent reticular pattern airspace opacification in the right lung
Initial lung computed tomography scan, a central cavitary mass lesion in the left upper lobe; pleural thickening and adjacent reticular pattern airspace opacification in the right lung
Figure 1.

Initial lung computed tomography scan, a central cavitary mass lesion in the left upper lobe; pleural thickening and adjacent reticular pattern airspace opacification in the right lung

Brain magnetic resonance imaging, T2-weighted imaging; A, initial imaging, increased signal intensity with surrounding edema in the right frontal lobe with a mild mass effect; B, follow-up imaging after three months, the number and size of the lesions increased
Brain magnetic resonance imaging, T2-weighted imaging; A, initial imaging, increased signal intensity with surrounding edema in the right frontal lobe with a mild mass effect; B, follow-up imaging after three months, the number and size of the lesions increased
Figure 2.

Brain magnetic resonance imaging, T2-weighted imaging; A, initial imaging, increased signal intensity with surrounding edema in the right frontal lobe with a mild mass effect; B, follow-up imaging after three months, the number and size of the lesions increased

Initially, the patient underwent empirical therapy with the following drugs: meropenem (500 mg every 8 hours), linezolid (600 mg every 12 hours), liposomal amphotericin B (0.25 mg daily), and hydrocortisone (50 mg every 8 hours). We administered the above antibiotics to cover bacterial and fungal etiologies of pyogenic brain abscesses. Also, because the patient’s general condition deteriorated, we changed the prednisolone (which the patient received daily) to a stress dose of hydrocortisone. During hospitalization, the patient did not respond to treatment. So, on the ninth day of hospitalization, bronchoalveolar lavage (BAL) and transbronchial lung biopsy (TBLB) were performed. Specimens obtained from TBLB revealed branched and septate hyphae. Besides, the culture of BAL specimens was positive for Aspergillus fumigatus (sensitive to voriconazole, itraconazole, and posaconazole; resistant to liposomal amphotericin B and caspofungin). As a result, we replaced intravenous voriconazole (6 mg/kg every 12 hours for the first day and 6 mg/kg every 12 hours for the next days) rather than amphotericin B. Then, the symptoms and level of consciousness improved dramatically. After three weeks of hospitalization, we discharged the patient in good general condition with oral voriconazole (200 mg every 12 hours).

At the follow-up three months later, the patient had no complaints while taking voriconazole. The lesions were cleared on a repeat lung CT scan. Amazingly, brain MRI illustrated an increase in the number and size of the lesions (Figure 2B). So, to explore the etiology of brain lesions, the patient was a candidate for stereotactic biopsy. Pathology findings confirmed an astrocytoma (grade III) in the right frontal lobe. According to the neurosurgery consultation, the patient did not indicate a surgical procedure. So, she was referred to radiotherapy.

3. Discussion

We report a known case of polymyositis with respiratory manifestations and an impaired level of consciousness. Imaging investigations revealed both pulmonary and cerebral involvement. Because the patient was treated with glucocorticoids for the long term, we considered her immunocompromised (4). Considering the lung and the brain involved simultaneously, we kept in mind the following infectious agents: Streptococcus angionosus, Staphylococcus aureus, Klebsiella pneumonia, Nocardia species, Mycobacterium tuberculosis, Aspergillus species, Mucor species and Cryptococcus neoformans (5). Thus, we prescribed empirical and broad-spectrum therapy. After a few days of treatment, her symptoms did not improve. So, additional diagnostic measures explored invasive pulmonary infection (IPI) caused by A. fumigatus.

Aspergillus species are found in outdoor environments (e.g., soil and dust) and indoor environments (e.g., hospitals). Despite constant inhalation by humans, it does not cause disease in individuals with an intact immune system (6). Invasive pulmonary aspergillosis (IPA), the most aggressive disease caused by it, mainly affects susceptible hosts. Patients with an impaired immune system (e.g., defects in neutrophil count or function, hematological malignancies, organ transplantation, and taking immunosuppressive drugs and corticosteroids) or underlying diseases (e.g., diabetes mellitus, chronic obstructive pulmonary disease) have a higher risk of developing IPA (7, 8). Although there is no pathognomonic radiological sign of IPA, imaging is considered a diagnostic pillar. Imaging investigation of patients with IPA commonly presents nodules, halo sign, cavity, and air crescent sign. These findings, accompanied by clinical clues and laboratory findings, contribute to a diagnosis (9).

Due to the nonspecific manifestation of IPA in non-neutropenic patients, it can mimic bacterial pneumonia. For this reason, early diagnosis of IPA is generally a diagnostic challenge (10). Physicians should consider a blend of clinical, laboratory, and imaging findings to diagnose. In recent years, different methods have been introduced for the diagnosis of IPA. Galactomannan (one of the components of the cell wall of fungi) detection is the gold standard for diagnosing IPA (11). In non-neutropenic patients, galactomannan (at the cut-off level ≥ 1 optical density index) has higher diagnostic accuracy in BAL fluid compared with serum (12). The first-line treatment for patients with IPA is voriconazole or isavuconazole for 6 - 12 weeks. Although voriconazole is well tolerated, it may rarely develop visual disturbances, skin rashes, and abnormal liver enzymes. In terms of therapeutic efficacy, isavuconazole is not superior to voriconazole. Nevertheless, it has less cost and drug-related adverse reactions compared to voriconazole. When it is impossible to administer first-line drugs, liposomal amphotericin B or caspofungin may help. Combination therapy is not recommended except for refractory patients. Surgical interventions may be advantageous in patients with massive hemoptysis or refractory disease (7, 10).

Cerebral aspergillosis commonly presents with hypointense lesions on T1-weighted and T2-weighted MRIs (13). In contrast, the brain lesions of our patient were hypointense on T1 weighted and hyperintense on T2 weighted and fluid-attenuated inversion recovery (FLAIR). It is a rare imaging finding of cerebral aspergillosis (14), which interestingly can mimic astrocytoma (15). Additionally, a brain biopsy is highly invasive and may cause neurologic deficits (16). Thus, assuming the identical etiology of pulmonary and cerebral lesions, we did not perform a brain biopsy and treated the patient with the diagnosis of aspergillosis. Gliomas are common tumors of the central nervous system. Anaplastic astrocytoma is a high-grade glioma that originates from astrocytes (17). It imposes considerable mortality and morbidity on affected adults, with a survival length of 2 - 5 years. Patients with grade III astrocytoma are commonly treated with surgical intervention, followed by chemotherapy or radiotherapy (18). The literature has provided evidence that pulmonary, renal, breast, bladder, endometrial, cervical, thyroid, and brain malignancies and lymphoma are associated with polymyositis (19). Although the mechanism of the increased risk of developing cancer in polymyositis patients is unclear, some studies attributed it to anti-transcriptional intermediary factor 1 (TIF1)-γ. Anti-TIF1-γ is an antibody produced against components of malignant cells, which has cross-reactivity with autoantigens. So, it can trigger some types of autoimmune myositis, including polymyositis (20).

3.1. Conclusions

Patients with polymyositis are prone to contracting opportunistic infections and malignancies. Both of them can mimic each other and present diagnostic challenges to physicians. Thus, it is important to consider them for early diagnosis and timely treatment.

Acknowledgements

References

  • 1.

    Yang SH, Chang C, Lian ZX. Polymyositis and dermatomyositis - challenges in diagnosis and management. J Transl Autoimmun. 2019;2:100018. [PubMed ID: 32743506]. [PubMed Central ID: PMC7388349]. https://doi.org/10.1016/j.jtauto.2019.100018.

  • 2.

    Wu C, Wang Q, He L, Yang E, Zeng X. Hospitalization mortality and associated risk factors in patients with polymyositis and dermatomyositis: A retrospective case-control study. PLoS One. 2018;13(2). e0192491. [PubMed ID: 29474373]. [PubMed Central ID: PMC5824989]. https://doi.org/10.1371/journal.pone.0192491.

  • 3.

    Sellami K, Mseddi M, Snoussi M, Gharbi H, Frikha F, Salah RB, et al. Malignancy in a retrospective cohort of 17 patients with Dermatomyositis or Polymyositis in southern Tunisia. Rom J Intern Med. 2018;56(4):243-9. [PubMed ID: 29791319]. https://doi.org/10.2478/rjim-2018-0015.

  • 4.

    Pilishvili T, Fleming-Dutra KE, Farrar JL, Gierke R, Mohr NM, Talan DA, et al. Interim estimates of vaccine effectiveness of Pfizer-BioNTech and Moderna COVID-19 vaccines among health care personnel - 33 U.S. sites, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(20):753-8. [PubMed ID: 34014909]. [PubMed Central ID: PMC8136422]. https://doi.org/10.15585/mmwr.mm7020e2.

  • 5.

    Leis JA, Bunce PE, Lee TC, Gold WL. Brain and lung lesions in an immunocompromised man. CMAJ. 2011;183(5):573-6. [PubMed ID: 20876264]. [PubMed Central ID: PMC3060186]. https://doi.org/10.1503/cmaj.100477.

  • 6.

    Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: a clinical review. Eur Respir Rev. 2011;20(121):156-74. [PubMed ID: 21881144]. [PubMed Central ID: PMC9584108]. https://doi.org/10.1183/09059180.00001011.

  • 7.

    Kanj A, Abdallah N, Soubani AO. The spectrum of pulmonary aspergillosis. Respir Med. 2018;141:121-31. [PubMed ID: 30053957]. https://doi.org/10.1016/j.rmed.2018.06.029.

  • 8.

    Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367-76. [PubMed ID: 31802125]. [PubMed Central ID: PMC7486838]. https://doi.org/10.1093/cid/ciz1008.

  • 9.

    Herrera S, Husain S. Current state of the diagnosis of invasive pulmonary aspergillosis in lung transplantation. Front Microbiol. 2018;9:3273. [PubMed ID: 30687264]. [PubMed Central ID: PMC6333628]. https://doi.org/10.3389/fmicb.2018.03273.

  • 10.

    Russo A, Tiseo G, Falcone M, Menichetti F. Pulmonary aspergillosis: An evolving challenge for diagnosis and treatment. Infect Dis Ther. 2020;9(3):511-24. [PubMed ID: 32638227]. [PubMed Central ID: PMC7339098]. https://doi.org/10.1007/s40121-020-00315-4.

  • 11.

    Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24 Suppl 1:e1-e38. [PubMed ID: 29544767]. https://doi.org/10.1016/j.cmi.2018.01.002.

  • 12.

    Zhou W, Li H, Zhang Y, Huang M, He Q, Li P, et al. Diagnostic value of galactomannan antigen test in serum and bronchoalveolar lavage fluid samples from patients with nonneutropenic invasive pulmonary aspergillosis. J Clin Microbiol. 2017;55(7):2153-61. [PubMed ID: 28446576]. [PubMed Central ID: PMC5483917]. https://doi.org/10.1128/JCM.00345-17.

  • 13.

    Khandwala K, Mubarak F, Minhas K, Gauhar F, Ahmed A. Giant central nervous system aspergilloma mimicking butterfly neoplasm of the corpus callosum. Cureus. 2022;14(6). e26225. [PubMed ID: 35891873]. [PubMed Central ID: PMC9308059]. https://doi.org/10.7759/cureus.26225.

  • 14.

    Lee GJ, Jung TY, Choi SM, Jung MY. Cerebral aspergillosis with multiple enhancing nodules in the right cerebral hemisphere in the immune-competent patient. J Korean Neurosurg Soc. 2013;53(5):312-5. [PubMed ID: 23908709]. [PubMed Central ID: PMC3730037]. https://doi.org/10.3340/jkns.2013.53.5.312.

  • 15.

    Ogunlade J, Wiginton J, Elia C, Odell T, Rao SC. Primary spinal astrocytomas: A literature review. Cureus. 2019;11(7). e5247. [PubMed ID: 31565645]. [PubMed Central ID: PMC6759039]. https://doi.org/10.7759/cureus.5247.

  • 16.

    McCarthy M, Rosengart A, Schuetz AN, Kontoyiannis DP, Walsh TJ. Mold infections of the central nervous system. N Engl J Med. 2014;371(2):150-60. [PubMed ID: 25006721]. [PubMed Central ID: PMC4840461]. https://doi.org/10.1056/NEJMra1216008.

  • 17.

    Hirtz A, Rech F, Dubois-Pot-Schneider H, Dumond H. Astrocytoma: A hormone-sensitive tumor? Int J Mol Sci. 2020;21(23). [PubMed ID: 33266110]. [PubMed Central ID: PMC7730176]. https://doi.org/10.3390/ijms21239114.

  • 18.

    Kapoor M, Gupta V. Astrocytoma. Treasure Island, USA: StatPearls; 2022.

  • 19.

    Hsu JL, Liao MF, Chu CC, Kuo HC, Lyu RK, Chang HS, et al. Reappraisal of the incidence, various types and risk factors of malignancies in patients with dermatomyositis and polymyositis in Taiwan. Sci Rep. 2021;11(1):4545. [PubMed ID: 33633147]. [PubMed Central ID: PMC7907377]. https://doi.org/10.1038/s41598-021-83729-5.

  • 20.

    De Vooght J, Vulsteke JB, De Haes P, Bossuyt X, Lories R, De Langhe E. Anti-TIF1-gamma autoantibodies: warning lights of a tumour autoantigen. Rheumatology (Oxford). 2020;59(3):469-77. [PubMed ID: 31883334]. https://doi.org/10.1093/rheumatology/kez572.